Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: Final results of JCOG0205

A combination of oral uracil-tegafur plus leucovorin (UFT + LV) is a safe regimen for adjuvant chemotherapy after hepatectomy in patients with colorectal cancer: Safety report of the UFT/LV study

“…In the JCOG0205 trial (22), the 3-year diseasefree survival, the primary endpoint of the study, was 79.3% in the UFT/LV group and 77.8% in the 5-fluorouracil/LV group (hazard ratio = 1.016, 91.3% confidence interval, 0.838 to 1.232, one-sided p = 0.0236), demonstrating the non-inferiority of UFT/LV therapy to 5-fluorouracil/LV therapy. The completion rate of protocol treatment was 78% in both groups combined, indicating good treatment continuity.…”

Adjuvant Systemic Chemotherapy for Stages II and III Colon Cancer after Complete Resection: A Clinical Practice Guideline

“…The other studies looking at this comparison did not report p values [18][19][20] or did not report on stage iii patients separately 21 . These studies have an unclear risk of bias: almost all domains in the Risk of Bias assessment were rated as having either a low or unclear risk of bias.…”

Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer

“…The postoperative survival of patients with primary colorectal cancer has been improving; a recent Japanese study reported 5-year disease-free survival (DFS) and overall survival (OS) rates for stage III colon/upper rectal cancer of 74.3% and 82.6%, respectively, after adjuvant chemotherapy with 5-fluorouracil (5-FU) and leucovorin (LV) over a 6-month period (1). Historically, oral fluoropyrimidines have been widely used postoperatively for 6-12 months as an adjuvant therapy for stage III colorectal cancer in Japan.…”